



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-7010

March 8, 2011

Mark Quinn
Executive Chairman
Clenergen Corporation
Bath House, 8 Chapel Place
Rivington Road, London, U.K. EC2A 3DQ

Re: Clenergen Corporation
Form 10-K for the Fiscal Year Ended October 31, 2010
Filed February 14, 2011
File No. 333-130286

Dear Mr. Quinn:

We have limited our review of your filing to your contacts with countries that have been identified as state sponsors of terrorism, and we have the following comments. Our review with respect to this issue does not preclude further review by the Assistant Director group with respect to other issues. At this juncture, we are asking you to provide us with information so we may better understand your disclosure.

Please respond to this letter within ten business days by providing the requested information, or by advising us when you will provide the requested response. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing the information you provide in response to these comments, we may have additional comments.

General

1. We note on page 16 in your Form 10-K that your agreement with BioPower Corporation covers Cuba. We also note on page 15 that you intend to produce certain materials for export to the Middle East, a region that can be understood to include Iran, Sudan, and Syria. Cuba, Iran, Sudan, and Syria are identified by the State Department as state sponsors of terrorism, and are subject to U.S. economic sanctions and export controls. We note that your Form 10-K does not include disclosure regarding contacts with the referenced countries. Please describe to us the nature and extent of your past, current, and anticipated contacts with Cuba, Iran, Sudan, and Syria, whether through subsidiaries, joint ventures, or other direct or indirect arrangements. Your response should describe any materials, goods, technology, information, and services that you have provided, or intend to provide, into Cuba, Iran, Sudan, and Syria, directly or indirectly; the nature and extent of any direct or indirect marketing or selling efforts in the referenced countries;

and any agreements, commercial arrangements, or other contacts you have had with the governments of the referenced countries or entities controlled by those governments.

2. Please tell us whether, to the best of your knowledge, understanding, and belief, any of the materials, goods, or technology you have provided or intend to provide, directly or indirectly, into Cuba, Iran, Sudan, and Syria, including any technology you have licensed to BioPower Corporation, or products derived from such technology, are controlled items included in the Department of Commerce's Commerce Control List.
3. Please discuss the materiality of any contacts with Cuba, Iran, Sudan, and Syria and whether those contacts constitute a material investment risk for your security holders. Address materiality in terms of qualitative factors that a reasonable investor would deem important in making an investment decision, including the potential impact of corporate activities upon a company's reputation and share value. As you may be aware, various state and municipal governments, universities, and other investors have proposed or adopted divestment or similar initiatives regarding investment in companies that do business with U.S.-designated state sponsors of terrorism. Your materiality analysis should address the potential impact of the investor sentiment evidenced by such actions directed toward companies that have contacts with Cuba, Iran, Sudan, or Syria.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to the company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In responding to our comments, please provide a written statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please contact Pradip Bhaumik, Special Counsel, at (202) 551-3333 or me at (202) 551-3470 if you have any questions about the comments or our review.

Sincerely,

Mark Quinn
Clenergen Corporation
March 8, 2011
Page 3

Cecilia Blye, Chief
Office of Global Security Risk

cc: Roger Schwall
Assistant Director
Division of Corporation Finance